Taysha Gene Therapies (TSHA) Competitors

Vaxart (NASDAQ:VXRT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Which has more risk & volatility, VXRT or TSHA?

Vaxart has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.

Which has preferable earnings & valuation, VXRT or TSHA?

Vaxart has higher earnings, but lower revenue than Taysha Gene Therapies. Vaxart is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$7.38M	13.95	-$82.46M	-$0.41	-1.41
Taysha Gene Therapies	$15.45M	27.33	-$111.57M	$0.63	3.27

Do insiders and institutionals hold more shares of VXRT or TSHA?

18.1% of Vaxart shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 2.6% of Vaxart shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media favor VXRT or TSHA?

In the previous week, Taysha Gene Therapies had 17 more articles in the media than Vaxart. MarketBeat recorded 23 mentions for Taysha Gene Therapies and 6 mentions for Vaxart. Taysha Gene Therapies' average media sentiment score of 0.63 beat Vaxart's score of 0.47 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxart	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is VXRT or TSHA more profitable?

Taysha Gene Therapies has a net margin of -229.67% compared to Vaxart's net margin of -431.61%. Taysha Gene Therapies' return on equity of -106.36% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxart	-431.61%	-110.46%	-62.78%
Taysha Gene Therapies	-229.67%	-106.36%	-49.16%

Does the MarketBeat Community prefer VXRT or TSHA?

Vaxart received 206 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 77.04% of users gave Taysha Gene Therapies an outperform vote while only 65.54% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Vaxart	Outperform Votes 310 65.54%	Underperform Votes 163 34.46%
Taysha Gene Therapies	Outperform Votes 104 77.04%	Underperform Votes 31 22.96%

Do analysts recommend VXRT or TSHA?

Vaxart presently has a consensus price target of $3.00, indicating a potential upside of 417.15%. Taysha Gene Therapies has a consensus price target of $6.63, indicating a potential upside of 221.60%. Given Vaxart's higher probable upside, equities analysts plainly believe Vaxart is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Taysha Gene Therapies	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Vaxart on 13 of the 17 factors compared between the two stocks.